Skip to main content
. 2019 Dec 30;318(2):H378–H390. doi: 10.1152/ajpheart.00302.2019

Fig. 1.

Fig. 1.

Inhibition of activin type II receptor (ACTRII)/TGFβ receptor (TGFBR) signaling after myocardial infarction (MI) is associated with preserved cardiac hypertrophy and increased skeletal muscle mass. A: heart relative weight [body weight (bw)] in sham and mice with MI treated with vehicle, Myo-Fc, or a combination of follistatin and a TGFβ receptor inhibitor (Fol + TGFi); n ≥ 10 mice/group. B–D: cardiac mRNA levels of myostatin (MSTN; B), growth differentiation factor-11 (GDF11; C), and inhibin A (D); inhibin βA-subunit (INHBA), n = 5 mice/group. E and F: cardiac MSTN (E) and total and phosphorylated (P) SMAD2,3 ratio (F) and representative blots; n ≥ 8 mice/group. G and H: cardiomyocyte cross-sectional area (G) and representative images (H); n = 6 mice/group. I: gastrocnemius muscle relative weight; n ≥ 10 mice/group. J: gastrocnemius total and P-SMAD2,3 ratio and representative blots; n = 8 mice/group. *P < 0.05 by 2-way ANOVA.